<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694962</url>
  </required_header>
  <id_info>
    <org_study_id>LDRT-SCov19</org_study_id>
    <nct_id>NCT05694962</nct_id>
  </id_info>
  <brief_title>Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia</brief_title>
  <official_title>Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Multicenter Phase II Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated BenQ Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies low-dose radiation therapy as a treatment for patients with&#xD;
      severe COVID-19 pneumonia to improve clinical status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare treatment of severe COVID-19 pneumonia between supportive care and standard of&#xD;
      care drug therapies versus supportive care and standard of care drug therapies plus low-dose,&#xD;
      whole-lung radiation therapy&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo 1.5Gy of single low-dose radiation therapy. After completion of study&#xD;
      treatment, patients are followed up at days 1-7, and 14 after last dose of intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>improvement of oxygen saturation in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Temperature in degrees (ËšC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Heart rate in beats per minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Systolic blood pressure in mm Hg Systolic blood pressure in mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respirations Respirations Respirations Respirations Respirations Respirations</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Respiratory rate in breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FiO2</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Fi02 in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEEP Tidal volume Tidal volume</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Positive end expiratory pressure (PEEP) in cm H20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Overall survival</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>Survival in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT can</measure>
    <time_frame>28 days after radiation therapy</time_frame>
    <description>CT scans with volume of consolidation measured in cubic centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Test</measure>
    <time_frame>28 days after radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Test</measure>
    <time_frame>28 days after radiation therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.) plus 1.5Gy single treatment of whole-lung radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>supportive care and standard of care drug therapies (i.e., glucocorticosteroids, Paxlovid, etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low-Dose Radiation Therapy</intervention_name>
    <description>1.5Gy single treatment of whole-lung radiation therapy</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have had a positive test confirming the diagnosis of COVID-19;&#xD;
&#xD;
          2. Have had clinical signs of severe acute respiratory syndrome or pneumonia (dyspnea,&#xD;
             cough, with need for oxygen support at the time of enrollment);&#xD;
&#xD;
          3. Have visible consolidations/ground glass opacities on chest x-ray or computed&#xD;
             tomography;&#xD;
&#xD;
          4. Have been on ventilator support for no longer than 5 calendar days prior to the&#xD;
             schedule date of delivery of low-dose radiation therapy;&#xD;
&#xD;
          5. They voluntarily participate in this clinical trial, gave informed consent and signed&#xD;
             the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received chest radiotherapy before&#xD;
&#xD;
          2. Bacteria, fungi and other infections other than novel coronavirus infection;&#xD;
&#xD;
          3. Combined with severe primary diseases such as cardiovascular, cerebrovascular, liver,&#xD;
             kidney, hematopoietic and endocrine system or immune system diseases (the upper limit&#xD;
             of liver function ALT and AST&gt; normal reference value, the upper limit of Scr&gt; normal&#xD;
             reference value, poor blood glucose control);&#xD;
&#xD;
          4. Mental retardation, mental disorders;&#xD;
&#xD;
          5. Planned pregnancy, pregnancy, lactation women and during the trial;&#xD;
&#xD;
          6. Allergy constitution or allergy to the drug ingredients and excipients of this test;&#xD;
&#xD;
          7. Participated in other clinical trials in the recent 1 month;&#xD;
&#xD;
          8. The Investigator does not considered appropriate to participate in this clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lirong Wu, M.D, Ph.D</last_name>
    <phone>13701588737</phone>
    <email>wulirong126@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xia He, M.D, Ph.D</last_name>
    <phone>+86-25-83283563</phone>
    <email>hexiabm@163.com</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>January 22, 2023</last_update_submitted>
  <last_update_submitted_qc>January 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Dr. He Xia</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

